The research, led by Wei Peng, Haijin Huang, Pinchao Yang and colleagues at Gannan Medical University, Sichuan University and collaborating institutions in Jiangxi Province, China, systematically compared R-propranolol, S-propranolol and the conventional racemic mixture in hemangioma endothelial cells, the so-called HemECs that constitute the pathological core of infantile hemangioma. The team combined laboratory assays of cell behavior with molecular docking, 100-nanosecond molecular dynamics simulations, RNA sequencing and pathway perturbation experiments, building what they describe as an integrative pipeline linking atomic-scale receptor interactions to whole-cell physiology. Their headline finding is striking: R-propranolol, the enantiomer that is actually the weaker beta-blocker at classical adrenergic receptors, emerged as the most potent suppressor of hemangioma endothelial cell survival and motility in vitro.

The quantitative differences were substantial. After 72 hours of treatment, R-propranolol reduced hemangioma endothelial cell viability to 44.2 plus or minus 3.5 percent of untreated controls, outperforming both the S-enantiomer and the racemate under identical conditions. Apoptosis, the programmed cell death that clinicians ultimately want to induce in these overgrown vascular lesions, rose to 20.1 plus or minus 0.6 percent with R-propranolol treatment, a marked elevation over comparator arms. Flow cytometric cell-cycle analysis revealed that the R-form drove a pronounced accumulation of cells in the G0/G1 quiescent phase, reaching 72.2 plus or minus 2.3 percent, effectively freezing the proliferative engine of the tumor at the checkpoint that precedes DNA replication. Perhaps most dramatic were the migration assays: where untreated hemangioma endothelial cells readily invaded a wound field with 435.3 plus or minus 48.6 migrating cells, R-propranolol treatment reduced this count to just 90.5 plus or minus 9.8, a roughly fivefold suppression of the migratory behavior that allows hemangiomas to expand locally.

To explain why one mirror-image molecule could outperform its twin, the investigators turned to structural biology. Propranolol’s two stereoisomers share an identical molecular formula and connectivity but differ in three-dimensional orientation, and this geometry governs how each form nestles into the binding pocket of the beta-2 adrenergic receptor, the principal molecular target implicated in hemangioma regression. Molecular docking calculations assigned R-propranolol a more favorable binding energy of minus 9.3 plus or minus 0.2 kilocalories per mole, indicating a tighter predicted fit within the receptor’s ligand-binding cavity. When the team extended the analysis to 100-nanosecond molecular dynamics simulations, which model the thermal motion of the protein-ligand complex in a solvated environment, the R-propranolol-beta-2 adrenergic receptor complex proved more conformationally stable, settling at an equilibrium root-mean-square deviation of only 0.18 plus or minus 0.02 nanometers. Binding free energy calculations using the MM-PBSA method, which decomposes the energetic contributions of electrostatics, van der Waals contacts and solvation, further favored the R-complex at minus 47.6 plus or minus 3.8 kilocalories per mole. Together, these computations paint a consistent biophysical picture in which the R-enantiomer forms a more durable engagement with the receptor implicated in the disease process.

But receptor binding alone could not tell the full story, because the downstream transcriptional consequences of each drug form remained unknown. The researchers therefore performed RNA sequencing on hemangioma endothelial cells treated with R-propranolol and compared the resulting gene expression profiles against controls. The treatment reprogrammed the transcriptome on a massive scale: 684 genes were significantly upregulated and 731 genes were downregulated. Enrichment analysis of these differentially expressed genes converged on one dominant signaling node, the PI3K-AKT pathway, a canonical pro-survival and pro-angiogenic cascade whose suppression has long been associated with the involution of infantile hemangioma. This finding places the stereochemical effect of propranolol squarely within a pathway that previous work, including studies demonstrating that propranolol downregulates the PI3K/Akt/eNOS/VEGF axis in hemangioma cells, has already linked to therapeutic response.

Crucially, the team did not stop at correlation. To test whether PI3K-AKT signaling was functionally responsible for the observed cellular effects, they carried out rescue experiments using insulin-like growth factor 1, or IGF-1, a potent upstream activator of the PI3K-AKT axis. When IGF-1 was supplied alongside R-propranolol, the drug’s characteristic changes were partially reversed: cell viability recovered to some degree, apoptosis declined, the G0/G1 cell-cycle block was loosened, and migratory capacity was partially restored. The partial nature of the rescue is itself informative, indicating that PI3K-AKT is a major but not exclusive mediator of R-propranolol’s action. Complementary experiments comparing the effects of pathway inhibitors further supported the involvement of PI3K-AKT-related signaling in mediating the drug’s anti-hemangioma activity, giving the causal chain from enantiomer, to receptor, to pathway, to cell fate an unusually complete architecture for a pharmacological study of this tumor.

The findings arrive at a moment of intense scientific interest in the stereochemistry of propranolol. The drug’s S-enantiomer is roughly 100-fold more potent as a classical beta-blocker at adrenergic receptors, which has long created a paradox for hemangioma therapy: the clinically administered racemate is dominated by the form that is the weaker blocker, and it nevertheless works. Several laboratories have recently reported that non-beta-blocker activities of propranolol, including effects on vasculogenesis, adipogenesis of hemangioma stem cells, and metabolic reprogramming via pathways such as the protein kinase RNA-like endoplasmic reticulum kinase cascade and hexokinase-2-mediated glycolysis, may be equally or more important than receptor antagonism. The new study adds a stereochemical dimension to this evolving picture, suggesting that the R-form, often dismissed as the pharmacologically inert half of the racemate, may in fact be the therapeutically decisive half where hemangioma endothelial cells are concerned.

For clinicians, the implications are tantalizing but must be handled with appropriate caution. This was a cell-based and computational study, not a clinical trial, and the concentrations and exposure conditions used in vitro cannot be directly translated into dosing recommendations for infants. Any move toward enantiomer-pure formulations of propranolol for infantile hemangioma would need to confront substantial regulatory, toxicological and economic hurdles, since stereochemically pure drugs require chiral synthesis, enantiomeric stability testing and dedicated pediatric safety evaluation. There is also the question of whether enhanced in vitro potency of the R-form would translate into better lesion regression in living tissue, where drug metabolism, plasma protein binding and the complex multicellular environment of a proliferating hemangioma, including hemangioma stem cells and pericytes, modulate the final biological effect. Cardiovascular safety, the principal dose-limiting concern for propranolol in infants, would likewise need re-examination for any purified enantiomer, since bradycardia and hypotension are class effects that may distribute differently between the two forms.

Nevertheless, the study’s integrative framework offers a template for how drug repurposing in rare pediatric tumors might be rationalized in the future. Rather than treating a racemate as a single chemical entity, the pipeline deployed here, combining enantiomer-resolved cellular pharmacology, receptor-level simulation, unbiased transcriptomics and functional rescue, treats stereochemistry as a design variable. The same approach could be applied to other chiral drugs in vascular anomaly therapy, including the beta-blocker atenolol, whose non-beta-blocker enantiomers have independently been shown to inhibit vasculogenesis in infantile hemangioma, and to the emerging class of PI3K/AKT/mTOR inhibitors now being explored for complex vascular malformations. If the stereochemical hypothesis holds up in preclinical animal models and eventually in carefully designed clinical studies, the standard treatment for the most common tumor of infancy could be refined at the level of molecular geometry, potentially improving efficacy while reducing the mass of pharmacologically unnecessary compound delivered to infants.

The work, published as volume 16, article 410 of 3 Biotech under the title “Differential effects and mechanistic associations of propranolol stereoisomers in infantile hemangioma endothelial cells,” was supported by the National Natural Science Foundation of China and the Ganzhou City Science and Technology Bureau. The authors, who include co-first authors Wei Peng, Haijin Huang and Pinchao Yang, with correspondence directed to Qian Liu and Haijin Liu, report no conflicts of interest, and the study received approval from the Scientific Research Ethics Committee of Gannan Medical University. Whether R-propranolol will one day be dispensed as a purified enantiomer for infants with proliferating hemangiomas remains an open question, but the study makes a compelling case that the mirror-image structure of a fifteen-year-old drug still holds secrets worth pursuing, and that the answer to better therapy for the smallest patients may lie in the subtle asymmetry of a single carbon atom.